Education
About Us
Working with TipRanks
Follow Us
Agios Pharma (AGIO)
NASDAQ:AGIO
AGIO Stock Chart & Stats
$43.63
-$0.03(-0.09%)
At close: 4:00 PM EST
$43.63
-$0.03(-0.09%)
Day’s Range― - ―
52-Week Range$23.42 - $62.45
Previous CloseN/A
Volume212.48K
Average Volume (3M)554.86K
Market Cap
$2.37B
Enterprise Value$1.43B
Total Cash (Recent Filing)$952.86M
Total Debt (Recent Filing)$44.52M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Feb 12, 2026EPS Estimate
-1.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.78
Shares Outstanding58,313,812
10 Day Avg. Volume626,531
30 Day Avg. Volume554,856
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.21
Price to Sales (P/S)51.14
P/FCF Ratio-4.77
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue31.82
Enterprise Value/Gross Profit37.70
Enterprise Value/Ebitda-3.23
Forecast
1Y Price Target
$49.20Price Target Upside12.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-7.4
Revenue Forecast (FY)$44.37M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe phase 3 SCD trial mirrors the phase 2 trial, providing familiarity with patient population and endpoints, which is seen as a positive aspect.
Market PotentialMitapivat demonstrated significant reductions in VOCs compared to placebo, with strong potential for success on both endpoints of Hb improvement and VOC reductions in Phase 3.
Regulatory MilestonesApproval in Saudi Arabia and a positive CHMP opinion for thalassemia subtypes support confidence in upcoming regulatory milestones.
Bears Say
Market UncertaintyThe company did not provide details about the REMS or other ongoing labeling discussions, making the commercial implications hard to assess.
Regulatory ChallengesThe inclusion of a black box warning and a stated REMS request poses a risk for the launch of mitapivat.
Stock Price ImpactThe extension of the PDUFA date was due to concerns about hepatocellular injury, leading to a decrease in stock price.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $23.41 and its highest was $62.45 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $2.37B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Feb 12, 2026 which is in 91 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Oct 30, 2025. The company reported -$1.78 earnings per share for the quarter, beating the consensus estimate of -$1.897 by $0.117.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.94.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 58,313,812 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.78 in its last earnings report, beating expectations of -$1.897. Following the earnings report the stock price went up 2.908%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$49.20 (12.77% Upside)
$49.20 (12.77% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 400.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $315.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.45%
12-Months-Change
Fundamentals
Return on Equity
-27.57%
Trailing 12-Months
Asset Growth
-22.66%
Trailing 12-Months
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with strong financial performance, global regulatory progress, and significant pipeline advancements. However, there are challenges with increased expenses and potential regulatory hurdles related to the REMS program.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$49.20
▲(12.77% Upside)
Technical Analysis
ImmunityBio
―
Denali Therapeutics
―
NewAmsterdam Pharma Company
―
Recursion Pharmaceuticals
―
Apogee Therapeutics
―
Ownership Overview
0.87% Insiders
26.60% Mutual Funds
0.20% Other Institutional Investors
55.02% Public Companies and
Individual Investors